Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Donesta Bioscience B.V. develops DONESTA®, an orally administered estetrol-based hormone therapy targeting vasomotor and genito‑urinary symptoms of menopause. Phase III clinical trials have demonstrated statistically significant reductions in vasomotor symptoms compared to placebo, with all co-primary efficacy endpoints met. Safety data are positive, supporting upcoming regulatory submissions in the US and EU. The company has entered into licensing agreements for commercialization in Canada, Europe, Latin America, Australia/New Zealand, Russia/CIS countries but continues to seek a partner for the US market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Donesta Bioscience B.V..